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I. Introduction
Several excellent guidelines already exist on treating patients who have ventricular arrhythmias ( Table 1) . The purpose of this document is to update and combine the previously published recommendations into one source approved by the major cardiology organizations in the United States and Europe. We have consciously attempted to create a streamlined document, not a textbook that would be useful specifically to locate recommendations on the evaluation and treatment of patients who have or may be at risk for ventricular arrhythmias. Thus, sections on epidemiology, mechanisms and substrates, and clinical presentations are brief, because there are no recommendations for those sections. For the other sections, the wording has been kept to a minimum, and clinical presentations have been confined to those aspects relevant to forming recommendations.
The reader should note that the recommendations, text, figures, and tables included in this executive summary represent a succinct summary of the more extensive evidence base, critical evaluation, supporting text, tables, figures, and references that are included in the full-text guidelines. Readers are strongly encouraged to refer to the full-text guidelines.
The final recommendations for indications for a diagnostic procedure, a particular therapy, or an intervention for management of patients with ventricular arrhythmias and prevention of sudden cardiac death summarize both clinical evidence and expert opinion. Classification of Recommendations and Level of Evidence are expressed in the ACC/AHA/ESC format as follows:
Classification of recommendations
. Class I: Conditions for which there is evidence and/or general agreement that a given procedure or treatment is beneficial, useful, and effective. . Class II: Conditions for which there is conflicting evidence and/or divergence of opinion about the usefulness/ efficacy of a procedure or treatment. * Class IIa: Weight of evidence/opinion is in favor of usefulness/efficacy. * Class IIb: Usefulness/efficacy is less well established by evidence/opinion. . Class III: Conditions for which there is evidence and/or general agreement that a procedure/treatment is not useful/effective and in some cases may be harmful.
Level of evidence
. Level of Evidence A: Data derived from multiple randomized clinical trials or meta-analyses. . Level of Evidence B: Data derived from a single randomized trial or nonrandomized studies.
. Level of Evidence C: Only consensus opinion of experts, case studies, or standard-of-care.
The schema for classification of recommendations and level of evidence is summarized in Table 2 , which also illustrates how the grading system provides an estimate of the size of treatment effect and an estimate of the certainty of the treatment effect.
Recommendations with respect to therapy have considered:
(1) The therapy to be offered (implantable cardioverterdefibrillator [ICD] , antiarrhythmic drugs, surgery, and miscellaneous other treatments) (2) The point at which therapy is offered (primary prevention for those who are at risk but have not yet suffered from a life-threatening ventricular arrhythmia or sudden cardiac 'death' episode, or secondary for those patients who have already experienced such arrhythmias or events), ( 3) The purpose of therapy (life preservation or symptom reduction/improved quality of life) (4) The etiology of the arrhythmia substrate (coronary heart disease, cardiomyopathy, or other conditions) Table 1 Clinical practice guidelines and policy statements that overlap with ACC/AHA/ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of SCD Not all therapeutic combinations are clinically relevant and many have no evidence base and probably will not have in the future because of the lack of clinical relevance or the relative rarity of the particular grouping. In many instances, the probable value of therapy may be reasonably inferred by the response of similar patients to specific therapies.
A. Prophylactic implantable cardioverterdefibrillator recommendations across published guidelines
The ACC/AHA/NASPE 2002 Guidelines Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices, 6 include a large number of recommendations on ICD therapy that merit attention.
Recommendations for prophylactic ICD implantation based on (EFs) have been inconsistent because clinical investigators have chosen different EFs for enrollment in trials of therapy, average values of the EF in such trials have been substantially lower than the cutoff value for enrollment, and subgroup analysis of clinical trial populations based on EF have not been consistent in their implications. Substantial differences among guidelines have resulted. However, no trial has randomized patients with an intermediate range of EFs. For instance, there is no trial that has specifically studied patients with a LVEF between 31% and 35%, and yet recommendations have been set for such patients on the basis of data derived from trials that studied groups with EFs less than or equal to 30%, others that enrolled patients with an EF less than or equal to 35%, and another that enrolled patients with an EF less than or equal to 40%. Recognizing these inconsistencies, this Guideline Writing Committee has decided to deal with the issue by constructing recommendations to apply to patients with an EF less than or equal to a range of values. The highest appropriate class of recommendation was then based on all trials that recruited patients with EFs within this range. In this way, potential conflicts between guidelines were reduced and errors due to drawing false conclusions relating to unstudied patient groups were minimized (see Table 3 ).
It is important to note that experts can review the same data and arrive at different interpretations. Attempting to homogenize heterogeneous trials invariably leads to varying interpretations of the trial data. Furthermore, differences between the United States and Europe may modulate how recommendations are implemented. Guidelines are composed of recommendations on the basis of the best available medical science; however, implementation of these recommendations will be impacted by the financial, cultural, and societal differences among individual countries.
B. Classification of ventricular arrhythmias and sudden cardiac death
This classification table is provided for direction and introduction to the guidelines ( Table 4) .
II. Incidence of sudden cardiac death
The geographic incidence of sudden cardiac death (SCD) varies as a function of coronary heart disease (CHD) prevalence in different regions. 3 Estimates for the United States 9-13 range from less than 200 000 to more than 450 000 SCDs annually, with the most widely used estimates in the range of 300 000 to 350 000 SCDs annually. 14 The variation is based, in part, on the inclusion criteria used in individual studies. Overall, event rates in Europe are similar to those in the United States, 3 with significant geographic variations reported.
The temporal definition of SCD strongly influences epidemiological data. 15 The proportion of all natural deaths due to SCD is 13% when a definition of 1 h from onset of symptoms is used. In contrast, the community-wide study in Maastricht, the Netherlands, reported that 18.5% of all deaths were SCD, using a 24-h definition. 16 The application of a 24-h definition of SCD increases the fraction of all natural deaths falling into the 'sudden' category but reduces the proportion of all sudden natural deaths that are due to cardiac causes. 15 Approximately 50% of all CHD deaths are sudden and unexpected, occurring shortly (instantaneous to 1 h) after the onset of a change in clinical status, with some geographical variation in the fraction of coronary deaths that are sudden. 17 The decreasing age-adjusted CHD mortality does not imply a decrease in absolute numbers of cardiac or SCDs 18, 19 because of the growth and aging of the United States and European populations and the increasing prevalence of chronic heart disease. 20 
Population subgroups and risk prediction
Three factors affect the ability to identify subjects and population subgroups at risk and consideration of strategies for prevention of SCD:
. The absolute numbers and event rates (incidence) among population subgroups ( Figure 1 ) . The clinical subgroups in which SCDs occur . The time-dependence of risk. 14 The overall incidence of SCD in the United States is 1 to 2/ 1000 population (0.1% to 0.2%) per year, with some variations in estimates based on differences in various sources of data. This large population base includes those victims whose SCDs occur as a first cardiac event, as well as those whose SCDs can be predicted with greater accuracy because they are included in higher risk subgroups ( Figure 1 ). Higher levels of risk resolution can be achieved by identification of more specific subgroups. However, the corresponding absolute number of deaths becomes progressively smaller as the subgroups become more focused, Sudden cardiac arrest Death from an unexpected circulatory arrest, usually due to a cardiac arrhythmia occurring within an hour of the onset of symptoms, in whom medical intervention (e.g., defibrillation) reverses the event.
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Classification by electrocardiography Nonsustained VT Three or more beats in duration, terminating spontaneously in less than 30 s.
VT is a cardiac arrhythmia of three or more consecutive complexes in duration emanating from the ventricles at a rate of greater than 100 bpm (cycle length less than 600 ms).
Monomorphic
Nonsustained VTwith a single QRS morphology. 7 Polymorphic Nonsustained VT with a changing QRS morphology at cycle length between 600 and 180 ms.
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Sustained VT VT greater than 30 s in duration and/or requiring termination due to hemodynamic compromise in less than 30 s.
Monomorphic Sustained VT with a stable single QRS morphology.
Polymorphic Sustained VT with a changing or multiform QRS morphology at cycle length between 600 and 180 ms.
Bundle-branch re-entrant tachycardia VT due to re-entry involving the His-Purkinje system, usually with LBBB morphology; this usually occurs in the setting of cardiomyopathy.
Bidirectional VT VT with a beat-to-beat alternans in the QRS frontal plane axis, often associated with digitalis toxicity. Exercise ECG is commonly used in the evaluation of patients with ventricular arrhythmias. Its most common application is for detection of silent ischemia in patients suspected of having underlying CHD. 22 In patients with known or silent CHD or cardiomyopathies, the presence of frequent PVCs during or after exercise has been associated with greater risk for serious cardiovascular events but not specifically to SCD. [23] [24] [25] However, exercise-induced PVCs in apparently normal individuals should not be used to dictate therapy unless associated with documented ischemia or sustained VT. The use of continuous or intermittent ambulatory recording techniques can be very helpful in diagnosing a suspected arrhythmia, establishing its frequency and relating symptoms to the presence of the arrhythmia. Silent myocardial ischemic episodes may also be detected.
VI. Ambulatory electrocardiography Recommendations

VII. Electrocardiographic techniques and measurements Recommendations
Class IIa
It is reasonable to use T-wave alternans for improving the diagnosis and risk stratification of patients with ventricular arrhythmias or who are at risk for developing lifethreatening ventricular arrhythmias. (Level of Evidence: A) Class IIb ECG techniques such as signal-averaged ECG, heart rate variability, baroflex sensitivity, and heart rate turbulence may be useful for improving the diagnosis and risk stratification of patients with ventricular arrhythmias or who are at risk of developing life-threatening ventricular arrhythmias. (Level of Evidence: B) ICD trials, especially Multicenter Automatic Defibrillator Implantation Trial (MADIT) II, have highlighted the need to develop novel tools in order to identify patients at highest risk of ventricular arrhythmias and SCD. Numerous modalities exist at present for assessing this risk but only 2 are currently approved by the U.S. Food and Drug Administration: signal-averaged ECG and T-wave alternans. However, heart rate variability and baroflex sensitivity also show considerable promise. 
A. Echocardiography
Echocardiography is the imaging technique most commonly used because it is inexpensive in comparison with other techniques such as MRI and cardiac CT, is readily available, and provides accurate diagnosis of myocardial, valvular, and congenital heart disorders associated with ventricular arrhythmias and SCD 26, 27 (Table 6 ). In addition, LV systolic function and regional wall motion can be evaluated, and in a majority of patients, EF can be determined. 28 
B. Radionuclide techniques
Myocardial perfusion SPECT using exercise or pharmacological agents is applicable for a selected group of patients suspected of having ventricular arrhythmias triggered by ischemia and who are unable to exercise or have resting ECG abnormalities that limit the accuracy of ECG for ischemia detection.
C. Coronary angiography
In patients with life-threatening ventricular arrhythmias or in survivors of SCD, coronary angiography plays an important diagnostic role in establishing or excluding the presence of significant obstructive CHD.
IX. Electrophysiological testing
Electrophysiological (EP) testing with intracardiac recording and electrical stimulation at baseline and with drugs has been used for arrhythmia assessment and risk stratification for SCD. EP testing is used to document inducibility of VT, guide ablation, evaluate drug effects, assess the risks of recurrent VT or SCD, evaluate loss of consciousness in selected patients with arrhythmias suspected as a cause, and assess the indications for ICD therapy. [29] [30] [31] [32] A. Electrophysiological testing in patients with coronary heart disease Recommendations Syncope is a transient symptom that may be caused by an underlying rhythm disorder with or without an associated cardiac disease. EP testing is used to document or exclude the arrhythmic cause of syncope. It is most useful in patients with CHD and LV dysfunction. EP testing is usually not the first evaluation step but rather complementary to a full syncope work-up. Lack of correlation between symptoms and a documented arrhythmia elicited during EP testing may lead to overinterpretation or underinterpretation of the predictive value of the results. Transient drug effects that can provoke syncope may remain undetected. Other causes such as a neurological etiology need to be considered in some patients.
X. Value of antiarrhythmic drugs
Use of antiarrhythmic drugs in the acute setting is described in Section XIII on Acute Management of Specific Arrhythmias.
The available antiarrhythmic drugs can be classified by the Vaughan Williams 4-level schema (type I: fast sodium channel blockers, type II: beta blockers, type III: repolarization potassium current blockers, type IV: calcium channel antagonists), 35 or by the more mechanistic and clinically relevant Sicilian Gambit. 36 The Vaughan Williams schema is somewhat outdated because antiarrhythmic drugs have complex actions that do not easily fit into 1 of the 4 specified classes of drug effects. This classification is of limited usefulness when choosing an antiarrhythmic drug to manage a specific arrhythmia. The Sicilian Gambit, introduced in 1991, was an attempt to provide a classification of antiarrhythmic drugs based on their mechanism of action and on arrhythmogenic mechanisms.
A. Beta blockers
These drugs are effective in suppressing ventricular ectopic beats and arrhythmias as well as reducing SCD in a spectrum of cardiac disorders in patients with and without heart failure (HF). Beta blockers are safe and effective antiarrhythmic agents that can be considered the mainstay of antiarrhythmic drug therapy. 37, 38 B. Amiodarone and sotalol
The overall long-term survival benefit from amiodarone is controversial, with most studies showing no clear advantage over placebo. A few studies and one meta-analysis of several large studies have shown reduction in SCD using amiodarone for LV dysfunction due to prior MI and nonischemic dilated cardiomyopathy (DCM), [39] [40] [41] but the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) showed no survival benefit from amiodarone when compared with placebo. 8, 42 Sotalol, like amiodarone, is effective in suppressing ventricular arrhythmias, but it has greater proarrhythmic effects and has not been shown to provide a clear increase in survival.
XI. Special considerations where antiarrhythmic drugs may be indicated
Amiodarone therapy may be considered in special situations 43 ; secondary subset analyses indicate possible survival benefit when amiodarone is combined with beta blockers. 44, 45 A. Patients with ventricular tachyarrhythmias who do not meet criteria for an implantable cardioverter-defibrillator Beta blockers are the first-line therapy, but if this therapy at full therapeutic dose is not effective, then amiodarone or sotalol can be tried with monitoring for adverse effects during administration.
B. Patients with implantable cardioverterdefibrillators who have recurrent ventricular tachycardia/ventricular fibrillation with frequent appropriate implantable cardioverterdefibrillator firing
This scenario, in its extreme, has been called defibrillator (tachycardia) storm, and it requires the addition of antiarrhythmic drugs and/or catheter ablation for control of the recurrent VT and associated ICD shocks. Sotalol is effective in suppressing atrial and ventricular arrhythmias, 46 the combination of beta blockers and amiodarone is an alternative approach. Intravenous amiodarone has been useful.
XII. Implantable and external cardioverter devices
Several prospective multicenter clinical trials have documented improved survival with ICD therapy in high-risk patients with LV dysfunction due to prior MI and nonischemic cardiomyopathy 8, [47] [48] [49] [50] [51] [52] [53] ( Figure 2 ). ICD therapy compared with conventional or traditional antiarrhythmic drug therapy has been associated with mortality reductions from 23% to 55% depending on the risk group participating in the trial, with the improvement in survival due almost exclusively to a reduction in SCD. The trials may be subcategorized into 2 types: primary prevention (prophylactic) trials in which the subjects have not experienced a lifethreatening ventricular arrhythmia or a symptomatic equivalent and secondary prevention trials involving subjects who have had an abortive cardiac arrest, a life-threatening VT, or unexplained syncope with work-up suggesting a high probability that a ventricular tachyarrhythmia was the cause of the syncope.
A. Automated external defibrillator
The automated external defibrillator (AED) saves lives when external defibrillation can be rendered within minutes of onset of VF. The AED represents an efficient method of delivering defibrillation to persons experiencing out-of-hospital cardiac arrest, and its use by both traditional and nontraditional first responders appears to be safe and effective. 54, 55 Appropriate device location to reduce time delay after onset of cardiac arrest is critical. Federal, state, and community efforts have been effective in placing AEDs in schools, sporting events, high-density residential sites, and airports as well as on airplanes and in police and fire department vehicles. The specific application of radiofrequency ablation to VT has evolved as the technology has developed. Radiofrequency ablation can be applied in the treatment of VT in patients with ischemic disease, cardiomyopathy, bundlebranch re-entry, and various forms of idiopathic VT. [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] 
C. Antiarrhythmic surgery
In patients with recurrent VT refractory to drugs, implanted defibrillators, and radiofrequency catheter ablation, direct surgical ablation or resection of the arrhythmogenic focus is an approach that continues to be used in experienced centers. Surgery requires accurate preoperative and intraoperative mapping to determine the site or sites of the tachycardia. Some centers use a scar-based approach to resecting arrhythmogenic sites.
Left cervicothoracic sympathetic ganglionectomy is associated with reduction in the frequency of arrhythmogenic syncope in the congenital LQTS and may be useful as adjunctive therapy in high-risk patients with long QT who have recurrent syncope and/or aborted cardiac arrest despite combined ICD and beta-blocker therapy or in patients with long QT who cannot tolerate beta blockers. 77 
D. Revascularization for arrhythmia management
A review of coronary revascularization studies reveals improved survival and reduction in SCD during long-term follow-up. 78, 79 If obstructive CHD is complicated by ventricular arrhythmias, especially in patients with left main and proximal left anterior descending coronary artery disease, there is a reasonable likelihood that revascularization will reduce the frequency and complexity of the arrhythmias and, in some patients, will eliminate such arrhythmias.
XIII. Acute management of specific arrhythmias A. Management of cardiac arrest
Cardiac arrest is characterized by an abrupt loss of effective blood flow, sufficient to cause immediate loss of consciousness, leading immediately to death if untreated. The most common electrical mechanisms for cardiac arrest are VF and pulseless VT (see Section 4 in the full-text guidelines), but substantial numbers of cardiac arrests begin as severe bradyarrhythmias, asystole, or pulseless electrical activity.
Recommendations
Class I
(1) After establishing the presence of definite, suspected, or impending cardiac arrest, the first priority should be activation of a response team capable of identifying the specific mechanism and carrying out prompt intervention. Advanced life support activities, other than those directly related to electrical methods for control of tachyarrhythmias, led to the generation of complex protocols to guide responders. These documents, published by the AHA 80 and the ERC, 81 cover the broad expanse of clinical circumstances and considerations of mechanisms. They provide management information, stratified for special circumstances such as age of the victim (from infancy to the elderly), pathophysiological status, and survival probabilities. The response algorithms to these various circumstances are complex and the reader is referred to the source documents for details.
80, 81 As management guidelines, these documents are classified as Level of Evidence C, but they are derived from a combination of varied studies and opinion that range from Levels of Evidence A, B, or C. Abbreviated versions for tachyarrhythmias and nontachyarrhythmic mechanisms are shown in Figure 3 in the full-text guidelines.
B. Arrhythmias associated with acute coronary syndromes
The incidence of VF (occurring within 48 h of the onset of the acute coronary syndrome [ACS]) may be decreasing owing to aggressive revascularization limiting infarct size and to increased beta-blocker use. 82 VF occurring early in the ACS has been associated with an increase in hospital mortality but not with increased long-term mortality. 83 Prophylaxis with lidocaine may reduce the incidence of VF in the ACS but appears to be associated with increased mortality, likely owing to bradycardia, and this treatment has largely been abandoned. 84 Use of prophylactic beta blockers in the setting of acute MI reduces the incidence of VF, and this practice is encouraged when appropriate. Similarly, correction of hypomagnesemia and hypokalemia is encouraged because of the potential contribution of electrolyte disturbances to VF. Correction of potentially causative or aggravating conditions such as hypokalemia and ischemia is an early priority. Timely termination is usually desirable even if VT is well tolerated. This can be achieved with cardioversion, antiarrhythmic medications, or pacing techniques.
Initial treatment often includes the administration of intravenous antiarrhythmic medication. The advantages include the lack of necessity for anesthesia and ready availability.
Intravenous amiodarone is not ideal for early conversion of stable monomorphic VT. Intravenous procainamide is more appropriate when early slowing of the VT rate and termination of monomorphic VT are desired. 86, 87 Close monitoring of blood pressure and cardiovascular status is recommended in the presence of congestive HF or severe LV dysfunction as intravenous procainamide can cause transient hypotension. 88 Lidocaine is effective when VT is thought to be related to myocardial ischemia. 89, 90 E. Repetitive monomorphic ventricular tachycardia
Recommendations
Class IIa
Intravenous amiodarone, beta blockers, and intravenous procainamide (or sotalol or ajmaline in Europe) can be useful for treating repetitive monomorphic VT in the context of coronary disease 91 
and idiopathic VT. (Level of Evidence: C)
Repetitive monomorphic VT is characterized electrocardiographically by frequent ventricular ectopy and salvos of nonsustained ventricular tachycardia (NSVT) with intervening sinus rhythm. It typically occurs at rest and is selfterminating, although the arrhythmia can be present for much of the time. 92 Although this terminology can refer to mechanistically diverse arrhythmias, it generally refers to idiopathic VT, most frequently the RV outflow type. [93] [94] [95] This tachycardia can cause palpitations or, rarely, tachycardia-related cardiomyopathy. 96 Many patients have no symptoms related to the arrhythmia. In some patients, tachycardia is provoked by exercise. 97 An electrocardiographically similar presentation is less frequent in patients with structural heart disease and, specifically, previous MI. 91 Beta-blocking agents or calcium channel blockers are often effective. Ablation is generally successful in problematic RV outflow tachycardia. 98 Polymorphic VT may be sustained, generally requiring urgent electrical cardioversion or self-terminating with interludes of sinus rhythm.
F. Polymorphic ventricular tachycardia Recommendations
Intravenous beta blockers are useful in this context and improve mortality in the setting of recurrent polymorphic VT with acute MI. 99 Intravenous loading with amiodarone is also useful. Marked QT interval prolongation and the morphologically distinctive polymorphic VT torsades de pointes occur in 3 common settings: congenital LQTS, a drug-associated form, and in patients with advanced conduction system disease that has progressed to heart block. 
I. Clinical features
The syndrome of very frequent episodes of VT requiring cardioversion has been termed 'VT storm.' Management guidelines for these syndromes rely on anecdotal evidence because they are rare, there are multiple potential underlying mechanisms, and no randomized trials have been conducted.
Intravenous beta blockade should be considered for a polymorphic VT storm as it is the single most effective therapy. It is of utmost importance to try and understand the substrate of incessant arrhythmias because if a diagnosis is established, a targeted treatment may be possible. Patients with chronic CHD manifest 3 general types of ventricular tachyarrhythmias: NSVT (defined as 3 or more repetitive ventricular beats in a row lasting up to 30 s in duration at a rate greater than 100 beats per minute), sustained VT, and cardiac arrest resulting from VT or VF. The cardiac mortality of patients with all types of ventricular tachyarrhythmias is high. The high mortality results from nonsudden, as well as sudden, cardiac death. These arrhythmias may result from myocardial ischemia, or effects of HF, in addition to primary electrical abnormalities.
Most NSVT in patients with chronic CHD is brief and does not cause symptoms. There is no evidence that suppression of asymptomatic NSVT prolongs life. The treatment of sustained VT in patients with chronic CHD should be tempered by the clinical manifestations produced by the tachycardia, as well as the frequency of episodes. Patients experiencing cardiac arrest due to VF that does not occur within the first 24 to 48 h of acute MI may be at risk for recurrent cardiac arrest.
All patients with CHD are at risk for SCD, and most SCD occurs in patients without severe LV dysfunction. ICD therapy is indicated to reduce the risk of SCD in 2 patient groups: patients whose LVEF is less than or equal to 40% as a result of prior MI and who have spontaneous NSVT and sustained monomorphic VT inducible by EP testing 50 and patients whose LVEF is less than 30% as a result of an MI that occurred greater than or equal to 40 d earlier when HF (NYHA functional class II or III symptoms) is present. 51 The use of antiarrhythmic agents may predispose the patient to proarrhythmic complications that might pose significant threats to life. Increasingly, the ICD is being used effectively to treat these arrhythmias, which in themselves may not be life-threatening, in order to avoid the relative ineffectiveness and adverse complications of pharmaceutical therapy. Congenital heart disease represents a diverse spectrum of anatomic and physiological defects with significant differences in respect to natural history, pre-and postoperative physiology as well as the risk of arrhythmias, appropriate therapies and risk of late SCD.
During infancy and childhood, greater than 75% of deaths in patients with congenital heart disease are in-hospital events, most occurring during the perioperative period. 105 The remaining deaths occur as out-of-hospital or emergency department events, often in patients with other congenital anomalies or sepsis.
Beyond 20 y of age, there is a progressive increase in the incidence of sudden and total cardiac mortality in postoperative congenital heart disease patients. 106 Five congenital heart defects have been associated with the greatest risks of late SCD: tetralogy of Fallot, d-and l-transposition of the great arteries, aortic stenosis, and functional single ventricle. [106] [107] [108] The largest number of late SCD studies in postoperative patients with congenital heart disease have been for tetralogy of Fallot. In general, postoperative patients with unexplained syncope should undergo both hemodynamic and EP evaluation. A positive response to EP testing, independent of the clinical indication, may identify patients with a high risk of late SCD. 109 In the absence of ventricular dysfunction or symptoms, isolated ventricular ectopy has minimal prognostic significance, and the risks of antiarrhythmic drug treatment can exceed any potential benefit. 110 The most common congenital coronary artery anomaly causing SCD in the young is anomalous origin of the left coronary artery from the right sinus of Valsalva. The proposed mechanism of SCD is that either acute angulation of the coronary ostium or compression of the left coronary artery as it traverses the region between the aortic wall and RV outflow tract results in acute myocardial ischemia and the development of VT or VF. Definitive diagnosis by coronary angiography is an indication for surgical revascularization.
Although disorders in this category are important causes of life-threatening ventricular arrhythmias, the occurrence of VT/SCD is relatively rare and, hence, in most cases, there are few trial data as to how the arrhythmias should best be managed. Data relating to the prevention of lifethreatening ventricular arrhythmias are even sparser.
Acute emergencies, as a consequence of any underlying ailment in this section, should be managed conventionally. Myocarditis is an inflammatory process affecting the cardiac myocardium and is most often related to infection.
D. Metabolic and inflammatory conditions
Cardiac arrhythmias associated with acute myocarditis can range from conduction abnormalities to difficult to suppress life-threatening ventricular arrhythmias. Death can occur related to HF and arrhythmias including heart block. [111] [112] [113] [114] [115] [116] [117] [118] Patients with arrhythmias or syncope may require antiarrhythmic drugs and/or device therapy. 119 Temporary pacemaker insertion is indicated in patients with acute myocarditis who present with symptomatic heart block as it would be in other causes of acute symptomatic heart block.
Lyme carditis patients can develop varying degrees of AV conduction abnormalities. Persistent heart block is rare, but in such cases permanent pacing may be needed. 120, 121 Chagas' disease is caused by the protozoan Trypanosoma cruzi and transmitted by an insect vector and is common in Central and South America. Acute myocarditis is rare, but over one third develop late myocardial damage with progressive HF and poor survival. Conduction defects with progression to complete heart block are common. Lifethreatening ventricular arrhythmias are common. Amiodarone appears to be effective in treating ventricular tachyarrhythmias, and death occurs as a result of either refractory HF or arrhythmias. 122 Device therapy including the ICD is frequently used in the late phase. 123 Acute rheumatic fever, complete heart block, and ventricular arrhythmias are rare. [124] [125] [126] The development of cardiac rhythm disturbances portends poorly in infective endocarditis. 127 
Infiltrative cardiomyopathies Recommendations
Class I
In addition to managing the underlying infiltrative cardiomyopathy, life-threatening arrhythmias should be treated in the same manner that such arrhythmias are treated in patients with other cardiomyopathies, including the use of ICD and pacemakers in patients who are receiving chronic optimal medical therapy and who have reasonable expectation of survival with a good functional status for more than 1 y. (Level of Evidence: C)
The association between the infiltrative cardiomyopathies and VT/SCD is well documented. In all cases, where appropriate, treatment of the underlying condition must accompany management of cardiac manifestations.
Endocrine disorders and diabetes
Recommendations Class I
(1) The management of ventricular arrhythmias secondary to endocrine disorders should address the electrolyte (potassium, magnesium, and calcium) imbalance and the treatment of the underlying endocrinopathy. Endocrine disorders can induce VT/SCD by excess or insufficient hormone activity on myocardial receptors (e.g., pheochromocytoma, hypothyroidism). The endocrinopathy can also cause myocardial changes (e.g., acromegaly) or electrolyte disturbances produced by hormone excess (e.g., hyperkalemia in Addison's disease and hypokalemia in Conn's syndrome) and certain endocrine disorders can accelerate the progression of conditions such as underlying structural heart disease secondary to dyslipidemia or hypertension, increasing the risk of serious arrhythmias. Extreme disorders of eating, and overzealous methods of rectifying them quickly, are all associated with SCD. In overweight individuals, this risk is particularly evident in the severely obese with a 40 to 60 times higher incidence compared to that in the age-matched general population. 128, 129 Obstructive sleep apnea may play a role in the genesis of arrhythmias and HF in obese individuals. 130 Reported mortality rates in anorexia nervosa fluctuate from 5% to 20%, but the actual rate is likely to be around 6%. 131 Up to a third of these deaths, including those occurring during re-feeding, are said to be due to cardiac causes but no precise data exist on SCD. SCD is responsible for 30% to 40% of mortality in patients with pulmonary arterial hypertension. The mortality of cardiac arrest survivors is high, even when the cause of the initial arrest appears to be a transient or correctable abnormality, and much of the mortality appears due to recurrent cardiac arrest. 132, 133 Observational studies suggest that . Sustained monomorphic VT in patients with prior MI is unlikely to be affected by revascularization.
E. Pericardial diseases Recommendations
G. Transient arrhythmias of reversible cause Recommendations
134
. Considerations taken by the Writing Committee in formulating recommendations for this section are discussed in detail in the Introduction.
Risk stratification
The 5-y mortality for DCM has been recently estimated at 20% with SCD accounting for approximately 30% (8% to 51%) of deaths. 136, 137 Ventricular arrhythmias, both symptomatic and asymptomatic, are common, but syncope and SCD are infrequent initial manifestations of the disease. 138, 139 The incidence of SCD is highest in patients with indicators of more advanced cardiac disease who are also at highest risk of all-cause mortality. Although VT and/or VF is considered the most common mechanism of SCD, bradycardia, pulmonary embolus, electromechanical dissociation, and other causes account for up to 50% of SCD in patients with advanced HF. [140] [141] [142] In controlled trials, amiodarone reduced the incidence of SCD in a population of patients with predominately nonischemic DCM 143 but not in a study of HF patients where the majority had CHD. 144 The ICD has been shown to be superior to amiodarone for secondary prevention of VT and VF in studies where the majority of patients had CHD. 49, 145, 146 The subgroup with nonischemic DCM in these studies benefited from the ICD more than those with CHD. 147 The Defibrillators in Nonischemic Cardiomyopathy Treatment Evaluation (DEFINTE) trial [148] [149] [150] randomized 458 patients with nonischemic DCM, EF less than 35%, and frequent PVCs or NSVT to receive best medical therapy with or without ICD. There was a trend toward reduction of mortality with ICD therapy, but this was not significant.
Genetic analysis
The clinical applicability of genetic analysis to DCM is still limited as knowledge in this area does not allow genotyping most individuals clinically affected by the disease. Patients with DCM and AV block and patients with DCM and skeletal muscle diseases have higher probability of being successfully genotyped. When a pathogenetic mutation is identified, it becomes possible to establish a presymptomatic diagnosis of the disease among family members and provide them with genetic counseling to monitor progression of the disease and to assess the risk of transmitting the disease to offspring. Based on current knowledge, genetic analysis does not contribute to risk stratification in DCM.
B. Hypertrophic cardiomyopathy
Recommendations Class I ICD therapy should be used for treatment in patients with hypertrophic cardiomyopathy (HCM) who have sustained VT and/or VF and who are receiving chronic optimal medical therapy and who have reasonable expectation of survival with a good functional status for more than 1 y. (Level of Evidence: B)
Class IIa
(1) ICD implantation can be effective for primary prophylaxis against SCD in patients with HCM who have one or more major risk factor (see Table 7 ) for SCD and who are receiving chronic optimal medical therapy and in patients who have reasonable expectation of survival with a good functional status for more than 1 y. (Level of Evidence: C) (2) Amiodarone therapy can be effective for treatment in patients with HCM with a history of sustained VT and/ or VF when ICD is not feasible. (Level of Evidence: C)
Class IIb
(1) EP testing may be considered for risk assessment for SCD in patients with HCM. (Level of Evidence: C) (2) Amiodarone may be considered for primary prophylaxis against SCD in patients with HCM who have one or more major risk factor for SCD (see Table 7 ), if ICD implantation is not feasible. (Level of Evidence: C)
Risk stratification
Most individuals with HCM are asymptomatic and the first manifestation may be SCD. [151] [152] [153] [154] [155] [156] [157] SCD is usually related to ventricular arrhythmia with a variable contribution of triggers such as ischemia, outflow obstruction, or atrial fibrillation. [153] [154] [155] [156] 158 This relatively low incidence creates a challenge for risk stratification since the false-positive results for any stratifier may overwhelm the true-positive results. 159 In one study, 23 of 480 patients died suddenly over a mean follow-up of 6.5 y. 160 The risk of SCD was directly related to LV wall thickness with essentially no mortality over 20 y with wall thickness less than 20 mm and almost 40% for wall thickness greater than or equal to 30 mm.
A consensus document on HCM from the ACC and ESC categorized the known risk factors for SCD as 'major' and 'possible in individual patients' 161 as follows in Table 7 . 
Management
The mainstay of pharmacological management for the symptomatic patient has been beta blockers or verapamil, which probably exert their effect by reducing heart rate and decreasing contractility. 153, 162 Amiodarone is widely used and considered the most effective antiarrhythmic agent, although large controlled comparative trials are not available. 163, 164 Although there are no randomized studies available, the ICD has been used in patients with cardiac arrest, sustained VT or VF with a high percentage of patients receiving appropriate discharge during follow-up at a rate of 11% per year. 165 
Genetic analysis
Genetic analysis is useful in families with HCM because whenever a pathogenetic mutation is identified, it becomes possible to establish a presymptomatic diagnosis of the disease among family members and to provide them with genetic counseling to assess the risk of disease development and transmission of the disease to offspring. Genetic analysis may contribute to risk stratification in selected circumstances. 
C. Arrhythmogenic right ventricular cardiomyopathy Recommendations
Risk stratification
Patients with arrhythmogenic RV cardiomyopathy ('dysplasia') have ventricular arrhythmias with left bundle-branch block morphology that span the spectrum of simple ventricular ectopy, sustained and NSVT, or VF. Unfortunately, SCD is frequently the first manifestation of the disease.
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Management
The ICD has been used in patients with unexplained syncope, sustained VT, or VF with a high incidence of appropriate shocks. 170 Although there are no specific large randomized trials in arrhythmogenic RV cardiomyopathy to support this, the situation is sufficiently 'similar' to those disease states such as previous MI where these indications are well established 49, [171] [172] [173] .
Genetic analysis
Genetic analysis is useful in families with RV cardiomyopathy because whenever a pathogenetic mutation is identified, it becomes possible to establish a presymptomatic diagnosis of the disease among family members and to provide them with genetic counseling to monitor the development of the disease and to assess the risk of transmitting the disease to offspring. Based on current knowledge, genetic analysis does not contribute to risk stratification of arrhythmogenic RV cardiomyopathy. The inherited neuromuscular disorders may predispose to atrial arrhythmias, conduction defects, advanced AV block, monomorphic VT, polymorphic VT, and SCD. [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] The clinical presentation, indicating the potential substrate for SCD, is quite variable because SCD is a wellrecognized complication of some of the neuromuscular diseases and progression of the conduction abnormalities may be unpredictable. [184] [185] [186] [187] [188] [189] [190] Once cardiac involvement occurs, particularly with the muscular dystrophies, the clinician should maintain a low threshold for investigating symptoms or ECG findings to determine the need for pacemaker insertion, invasive EP studies, or ICD implantation.
D. Neuromuscular disorders Recommendations
XVI. Heart failure
(1) ICD therapy is recommended for secondary prevention of SCD in patients who survived VF or hemodynamically unstable VT, or VT with syncope and who have an LVEF less than or equal to 40%, who are receiving chronic optimal medical therapy and who have a reasonable expectation of survival with a good functional status for more than 1 y. (Level of Evidence: A) (2) ICD therapy is recommended for primary prevention to reduce total mortality by a reduction in SCD in patients with LV dysfunction due to prior MI who are at least 40 d post-MI, have an LVEF less than or equal to 30% to 40%, are NYHA functional class II or III, are receiving chronic optimal medical therapy, and who have reasonable expectation of survival with a good functional status for more than 1 y. (Level of Evidence: A) (See Section IA.) (3) ICD therapy is recommended for primary prevention to reduce total mortality by a reduction in SCD in patients with nonischemic heart disease who have an LVEF less than or equal to 30% to 35%, are NYHA functional class II or III receiving chronic optimal medical therapy, and who have reasonable expectation of survival with a good functional status for more than 1 y. ( Class IIb
(1) Amiodarone, sotalol, and/or beta blockers may be considered as pharmacological alternatives to ICD therapy to suppress symptomatic ventricular tachyarrhythmias (both sustained and nonsustained) in optimally treated patients with HF for whom ICD therapy is not feasible.
(Level of Evidence: C) (2) ICD therapy may be considered for primary prevention to reduce total mortality by a reduction in SCD in patients with nonischemic heart disease who have an LVEF of less than or equal to 30% to 35%, are NYHA functional class I receiving chronic optimal medical therapy, and who have a reasonable expectation of survival with a good functional status for more than 1 y. (Level of Evidence: B) (See Section IA.)
Considerations taken by the Writing Committee in formulating recommendations for this section are discussed in detail in the Introduction.
Ventricular arrhythmias and SCD are common in patients with symptomatic acute and chronic HF and LV systolic dysfunction. The cause of HF likely influences the mechanisms and types of ventricular arrhythmias. The guidelines and comments in this section refer to patients with symptomatic HF; not just abnormal LVEF (refer to the ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult for definitions 6 ). In the setting of acute HF, ventricular arrhythmias may be especially poorly tolerated and early cardioversion should be performed, rather than attempting pharmacological termination of arrhythmia.
There is no evidence that suppression of NSVT has a favorable effect on prognosis in patients with HF. 144 Thus, asymptomatic NSVT should not be treated by antiarrhythmic medication. If NSVT causes symptoms that require therapy, amiodarone is probably the safest agent to use for treatment.
SCD accounts for approximately 50% of deaths in patients with HF. However, there is little evidence that empiric antiarrhythmic therapy can reduce the risk of SCD.
The SCD-HeFT trial showed no survival benefit to patients with HF (NYHA functional class II and III) and LVEF less than or equal to 35% treated with amiodarone empirically. 8 ICD therapy has not improved survival of patients with HF due to nonischemic DCM in 2 small trials. 191, 192 However, the SCD-HeFT trial demonstrated a 23% reduction in total mortality with ICD treatment in comparison to placebo. 8 These results are consistent with results of DEFINTE and earlier trials of patients with CHD and LV dysfunction, some of whom had symptomatic HF. 47, 50, 51 ICD in combination with biventricular pacing may improve survival and improve symptoms of patients with advanced HF (NYHA functional class III and IV) over short-term follow-up (1 to 2 y).
The value of biventricular pacing without additional ICD support for the reduction of SCD remains controversial. 193, 194 XVII. Genetic arrhythmia syndromes A. General concepts for risk stratification LQTS, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia (Online Mendelian 195 are inherited arrhythmogenic diseases. They share genetically determined susceptibility to VT and SCD in the absence of recognizable structural abnormalities of the heart. These syndromes are by definition rare diseases because they have an estimated prevalence below 5 in 10 000. Even before the identification of the genetic subtypes, QT interval duration was identified as the strongest predictor of risk for cardiac events (syncope, SCD) in LQTS, 197 and it remains so. A normal QT interval in an ungenotyped family member portends a good prognosis. 198 A QTc exceeding 500 ms (corresponding to the upper QTc quartile among affected genotyped individuals) identifies patients with the highest risk of becoming symptomatic by age 40 y. 199 Patients with the Jervell Lange-Nielsen and other homozygous syndromes and patients with LQTS associated with syndactyly 200, 201 are at higher risk. Patients resuscitated from SCD have an especially ominous prognosis with a relative risk of 12.9 of experiencing another cardiac arrest. 202 Syncope in LQTS patients is usually attributed to severe ventricular arrhythmias, although other causes can occur.
Lifestyle changes
It is recommended that all patients affected by LQTS avoid competitive sports activity. 203 For LQT1 patients, swimming should be specifically limited or performed under supervision. LQT2 patients should avoid exposure to acoustic stimuli especially during sleep (avoidance of telephone and alarm clock on the nightstand). All patients with LQTS should avoid drugs known to prolong the QT interval and those that deplete potassium/magnesium.
Genetic analysis
Genetic analysis is very important for identifying all mutation carriers within an LQTS family: Once identified, silent carriers of LQTS genetic defects may be treated with beta blockers for prophylaxis of life-threatening arrhythmias. Furthermore, silent mutation carriers should receive genetic counseling to learn about the risk of transmitting LQTS to offspring.
In patients affected by LQTS, genetic analysis is useful for risk stratification 199 and for making therapeutic decisions. 204 Although genetic analysis is not yet widely available, it is advisable to try to make it accessible to LQTS patients.
Andersen syndrome
Little is known about risk stratification and management of patients with Andersen syndrome. Patients seem to have ventricular arrhythmias but not a high incidence of cardiac arrest: The benefit of prophylactic treatment with beta blockers has not been defined even if most patients with prolonged QT are usually treated with these agents on empiric grounds. The beneficial role of calcium channel blockers has also been proposed on the basis of the arrhythmia-suppression observed in a single patient. The Brugada syndrome is associated with a characteristically abnormal ECG and a high risk of SCD in individuals with a structurally normal heart. 206 SCD is caused by rapid polymorphic VT or VF frequently occurring at rest or during sleep. Quinidine and isoproterenol may be useful in patients with arrhythmia storm even in the presence of an ICD. [207] [208] [209] Genetic analysis-Brugada syndrome Genetic analysis may help identify silent carriers of Brugada syndrome-related mutations so that they can remain under clinical monitoring to detect early manifestations of the syndrome. Furthermore, once identified, silent mutation carriers should receive genetic counseling and discuss the risk of transmitting the disease to offspring. Based on current knowledge, genetic analysis does not contribute to risk stratification.
Genetic analysis-short QT syndrome
Genetic analysis may help identify silent carriers of short QT syndrome related mutations; however, the risk of cardiac events in genetically affected individuals with a normal ECG is currently not known. The risk is also unknown because of the limited number of patients with short QT syndrome identified to date. At present, genetic analysis does not contribute to risk stratification. Catecholaminergic polymorphic VT is characterized by ventricular tachyarrhythmias that develop during physical activity or acute emotion in the presence of an unremarkable resting ECG. 210 
D. Catecholaminergic polymorphic ventricular tachycardia Recommendations
Genetic analysis
Genetic analysis may help identify silent carriers of catecholaminergic VT related mutations; once identified, silent carriers may be treated with beta blockers to reduce the risk of cardiac events and may receive appropriate genetic counseling to assess the risk of transmitting the disease to offspring. Based on current knowledge, genetic analysis does not contribute to further risk stratification. Demographics and presentation of outflow tract ventricular tachycardia VT arising from the right ventricle is the most common form of VT in apparently healthy people and is associated with a good prognosis in those without overt structural heart disease. 73, 76, 93, 97, [211] [212] [213] [214] [215] [216] [217] [218] [219] [220] [221] This VT usually has a left bundlebranch, inferior axis morphology.
XVIII. Arrhythmias in structurally normal hearts
Clinical treatment of RVOT or LVOT VT often involves beta and calcium-channel blockers. Type IC antiarrhythmic drugs have been found useful in RVOT VT. 97, 214, [222] [223] [224] [225] In patients who remain symptomatic or who fail drug therapy, catheter ablation of the arrhythmia focus in the RVOT should be considered.
So-called idiopathic LV VT can arise from the LVOT or from the fascicles of the specialized conduction system. Left fascicular VT typically is reentrant and may respond to beta blockers or to calcium-channel blockers. A rapid rise in extracellular potassium, hypokalemia (less than 3.5 mM), and hypomagnesemia are all associated with ventricular arrhythmias and SCD in patients with structurally normal hearts (some of whom may have underlying channelopathies) and in an acute MI setting. [226] [227] [228] [229] [230] [231] [232] [233] [234] [235] [236] [237] [238] [239] [240] Hypomagnesemia is classically associated with polymorphic VT or torsades de pointes, which together with ventricular arrhythmias in an acute MI setting, may respond to intravenous magnesium. [241] [242] [243] [244] Hypokalemia with or without hypomagnesemia may be responsible for ventricular arrhythmias in subjects with hypertension and congestive cardiac failure (precipitated by the use of thiazide and loop diuretics), 227, 228, 245 acute starvation, 246 acute alcohol toxicity/withdrawal, and those with ventricular arrhythmias associated with digoxin and other Vaughan Williams class III antiarrhythmic drugs. 238, 247, 248 Significant hypocalcemia can prolong the QT interval. The relationship between alcohol ingestion and VT/SCD is indisputable; what is controversial however, is its exact nature. 249 A number of studies claim a J-shaped relationship with risk lowest in individuals with low alcohol intake (i.e., 2 to 6 drinks per week) compared to those who rarely or never consume alcohol 250 and those with a high alcohol intake (i.e., greater than 3 to 5 drinks per day) 251, 252 and binge drinking habits, the so called 'holiday heart syndrome'. Cigarette smoking is an independent risk factor for SCD irrespective of underlying CHD. [257] [258] [259] [260] [261] Cessation of smoking significantly reduces risk of SCD. The association of high total, VLDL, or LDL cholesterol levels, a low HDL cholesterol level together with high triglyceride and apolipoprotein B levels with increased risk of VT/ SCD is almost entirely due to concurrent CHD. The effect of lipid lowering on SCD in primary prevention has not been addressed but a relative risk reduction of 30% to 40% would be expected in parallel with the reduction in the risk of CHD death. 262, 263 Free fatty acid or nonesterified fatty acid levels are also an independent risk factors for SCD but not fatal MI. It is generally accepted that preparticipation screening for medical conditions should be a requirement for clearance to participate in competitive athletics, but there are no uniformly accepted standards for screening.
B. Electrolyte disturbances
C. Physical and toxic agents
The major causes of SCD in athletes are HCM (36%) and coronary artery anomalies (19%), arrhythmogenic RV cardiomyopathy, and myocarditis.
Screening of athletes is a difficult task. The low incidence of anomalies makes screening not very cost effective, although one study has suggested that ECG screening is more cost effective than echocardiographic screening. QT interval Typically, women have longer QT intervals than do men, and this difference is more pronounced at slower heart rates. The incidence of both congenital and acquired forms of long QT intervals and resultant torsades de pointes is higher in women than in men. 197, 267 Palpitations are extremely common during pregnancy and several studies have shown an increase in the symptoms of supraventricular tachycardia (SVT) during pregnancy. [268] [269] [270] VT occurs in the absence of overt structural heart disease and may be related to elevated catecholamines. 271 As such, these arrhythmias may be beta-blocker sensitive. In women presenting with new onset VT during the last 6 wk of pregnancy or in the early postpartum period, the possibility of postpartum cardiomyopathy should be ruled out. 272 Potentially life-threatening ventricular tachyarrhythmias should be terminated by electrical cardioversion. Beta 1-selective beta blockers alone, amiodarone alone (noting cautions about birth defects above) or in combination may be used, and ICD may be needed as its presence does not contraindicate future pregnancies. Ventricular arrhythmias are common in elderly populations and the incidence increases in the presence of structural heart disease. [273] [274] [275] [276] Complex ventricular arrhythmias often presage new major coronary events and SCD in patients with CHD and other types of structural heart disease. 277, 278 The incidence of SCD increases with advancing age. 279, 280 The management of ventricular arrhythmias and the prevention of SCD in elderly patients do not differ appreciably from that recommended for the general population. Despite the demonstrated efficacy in reducing all-cause mortality and SCD, beta blockers are underused in the elderly.
C. Elderly patients Recommendations
Several randomized, prospective trials have demonstrated the efficacy of ICDs in reducing SCD in patients with CHD at high risk for SCD (primary prevention) and in patients resuscitated from SCD (secondary prevention) when compared with antiarrhythmic drug therapy across all age groups. 47, [49] [50] [51] 145, 146 All previously referenced studies included substantial numbers of patients over the age of 65 y. Subgroup analysis in Antiarrhythmics Versus Implantable Defibrillators (AVID) and MADIT II trials demonstrated equivalent benefits from ICD implantation in older and younger patients. 49, 51 Several observational studies have shown that the invasive approach in managing patients with life-threatening ventricular arrhythmias is equally beneficial in the elderly and in younger patients. [281] [282] [283] Very elderly patients with multiple comorbidities and limited life expectancy may not be appropriate candidates for ICD therapy even if they meet standard criteria. The incidence of SCD due to cardiovascular disease is significantly less in pediatric than adult patients.
D. Pediatric patients Recommendations
Several groups of young patients have been identified who are at an increased risk of SCD compared to the general population. These include patients with congenital heart disease, coronary artery anomalies, cardiomyopathies, and primary arrhythmic diagnoses such as the LQTSs. 284 Sustained ventricular arrhythmias may also occur in infants, most commonly an accelerated idioventricular rhythm. VF and SCD have been reported in these infants, most often following the administration of intravenous digoxin or verapamil for a presumptive diagnosis of SVT. 285, 286 Beyond the first year of life, most children with complex ectopy or hemodynamically tolerated VT appear to have a good prognosis. 287, 288 The role and benefit of ICD implantation for prevention of SCD in young children with advanced ventricular dysfunction have not been defined. In older children and adolescents, prophylactic ICD implantation may be considered, based on data derived from adult randomized clinical trials of similar patients. The placement of an ICD does not, in itself, decrease the incidence of arrhythmias, although the patient is protected from the consequences of the arrhythmias.
SVT may trigger ICD action due to fulfilling programmed ventricular or SVT detection criteria. Atrial fibrillation is the most frequent culprit arrhythmia.
Dual-chamber ICDs provide improved atrial diagnostic features with recording of local atrial electrograms, regularity of atrial signals, and cycle lengths.
High drug concentrations due to overdose or drug interactions generally increase risk of drug-induced arrhythmias. Certain arrhythmias are typical: enhanced atrial, junctional, or ventricular automaticity (with ectopic beats or tachycardia) often combined with AV block.
In mild cases, management includes discontinuing the drug, monitoring rhythm, and maintaining normal serum potassium. Occasionally, temporary pacing may be needed. For more severe intoxication (serum digoxin concentration greater than 4 to 5 ng/mL, and with serious arrhythmias), the treatment of choice is digoxin-specific Fab antibody. Marked QT prolongation, often accompanied by the morphologically distinctive polymorphic VT 'torsades de pointes,' occurs in 1% to 10% of patients receiving QT prolonging antiarrhythmic drugs, and much more rarely in patients receiving 'noncardiovascular' drugs with QT prolonging potential. Table 9 lists those generally recognized as having QT prolonging potential. An up-to-date list is maintained at www.torsades.org and www.qtdrugs.org.
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QT intervals, uncorrected for rate, are generally greater than 500 msec, prominent U waves are common, and marked QTU prolongation may only be evident on post-pause beats. Major risk factors for drug-induced torsades de pointes are listed in Table 10 ; often more than one is present. Drugs can expose subclinical congenital LQTS; in addition, some studies have implicated more common DNA variants (polymorphisms, with frequencies ranging up to 15% of some populations). 291, 292 Intravenous magnesium can suppress episodes of torsades de pointes without necessarily shortening QT, even when serum magnesium is normal. 293 Temporary pacing is highly effective in managing torsades de pointes that is recurrent after potassium repletion and magnesium supplementation.
H. Sodium channel blocker-related toxicity Recommendations
Class I
In patients with sodium channel blocker-related toxicity, removal of the offending agent is indicated. Arrhythmias caused by sodium channel blocking drugs are included in Table 11 . Antiarrhythmic drugs are the most common precipitants, although other agents, notably tricyclic antidepressants and cocaine, may produce some of their toxicities through these mechanisms. In large clinical trials, sodium channel blocking drugs have increased mortality among patients convalescing from myocardial infarction.
Animal and clinical anecdotes suggest that administration of sodium, as sodium chloride or sodium bicarbonate, may be effective in the reversing conduction slowing or frequent or cardioversion-resistant VT. 295, 296 Beta blockers have also been used successfully. 297 
I. Tricyclic antidepressant overdose
Tricyclic antidepressants are second only to analgesics as a cause of serious overdose toxicity. Typical cardiac manifestations include sinus tachycardia, and PR and QRS prolongation and occasionally a Brugada syndrome-like ECG. 298 QRS duration can be shortened in experimental animals and in humans by administration of NaHCO 3 or NaCl boluses. 299 Antipsychotic agents well known to produce marked QT prolongation and torsades de pointes include thioridazine and haloperidol. Anthracycline cardiotoxicity is dose dependent with intermittent high doses and higher cumulative doses increasing the risk of cardiomyopathy and lethal arrhythmias. 300, 301 Risk factors include younger age, female gender, and use of trastuzimab. 300, [302] [303] [304] This form of cardiomyopathy can occur acutely soon after treatment, within a few months of treatment (the so called subacute) form, or many years later. 301, [305] [306] [307] [308] [309] [310] [311] 5-Fluorouracil causes lethal and potentially fatal arrhythmias irrespective of underlying coronary disease during the acute infusion period, the vast majority during the first administration. 312 Cardiac monitoring during the infusion period, especially the first, is recommended for all patients receiving 5-fluorouracil therapy.
Cocaine has both slow offset sodium channel-blocking properties as well as QT-prolonging (I Kr -blocking) properties. Arrhythmias associated with cocaine ingestion include widecomplex tachycardias suggestive of sodium channel block (and responding to sodium infusion) as well as torsades de pointes. Cocaine also causes other cardiovascular complications that can lead to arrhythmias, notably myocarditis and coronary spasm.
XX. Conclusions
SCD continues to be a major cause of mortality in all developed countries. Using an evidence-based approach, this document attempts to summarize the latest information addressing the problem, trying as much as possible to provide recommendations consistent with previous documents. However, it is important to stress that the field is evolving and recommendations will certainly change as we learn more about the problem. The lengthy list of references serves as an indication of the large amount of research addressing SCD already, and undoubtedly, the list will continue to grow in the future. Timely updates of this information will be critical as we try to care for patients at risk of SCD. 
